Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based modelAnahita Rabiee, Guadalupe García–Tsao, Yanhong Deng et al.|Hepatology Communications|2022Cited by 48
Incidence and Clinical Significance of Recompensation After HCV CureGeorg Semmler, Heiner Wedemeyer, Martin Kabelitz et al.|Clinical Gastroenterology and Hepatology|2025Cited by 17
Severe alpha-1 antitrypsin deficiency is associated with a higher risk of complications after first decompensation than other aetiologies of cirrhosisLorenz Balcar, Mattias Mandorfer, Malin Fromme et al.|JHEP Reports|2025Cited by 2
SAT-381 Rapid liver disease progression after first hepatic decompensation in individuals with severe alpha-1 antitrypsin deficiency (Pi*ZZ genotype)Lorenz Balcar, Mattias Mandorfer, Malin Fromme et al.|Journal of Hepatology|2025Cited by 0
WED-198 Incidence and clinical significance of recompensation after HCV- cureGeorg Semmler, Mattias Mandorfer, Sabela Lens et al.|Journal of Hepatology|2025Cited by 0